209 related articles for article (PubMed ID: 11451623)
1. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
Anderson PW; Cox DA; Sashegyi A; Paul S; Silfen SL; Walsh BW
Maturitas; 2001 Jul; 39(1):71-7. PubMed ID: 11451623
[TBL] [Abstract][Full Text] [Related]
2. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.
Christodoulakos GE; Lambrinoudaki IV; Panoulis CP; Papadias CA; Kouskouni EE; Creatsas GC
Gynecol Endocrinol; 2004 May; 18(5):244-57. PubMed ID: 15346660
[TBL] [Abstract][Full Text] [Related]
3. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
Walsh BW; Kuller LH; Wild RA; Paul S; Farmer M; Lawrence JB; Shah AS; Anderson PW
JAMA; 1998 May; 279(18):1445-51. PubMed ID: 9600478
[TBL] [Abstract][Full Text] [Related]
4. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.
Smolders RG; Vogelvang TE; Mijatovic V; van Baal WM; Neele SJ; Netelenbos JC; Kenemans P; van der Mooren MJ
Maturitas; 2002 Feb; 41(2):105-14. PubMed ID: 11836041
[TBL] [Abstract][Full Text] [Related]
5. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
Vogelvang TE; Mijatovic V; van der Mooren MJ; Pinsdorf U; von Bergmann K; Netelenbos JC; Lütjohann D
Maturitas; 2005 Apr; 50(4):312-20. PubMed ID: 15780532
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial.
Vigna GB; Donegà P; Zanca R; Barban A; Passaro A; Pansini F; Bonaccorsi G; Mollica G; Fellin R
Metabolism; 2002 Nov; 51(11):1463-70. PubMed ID: 12404199
[TBL] [Abstract][Full Text] [Related]
7. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women.
Tsai KS; Yen ML; Pan HA; Wu MH; Cheng WC; Hsu SH; Yen BL; Huang KE
Osteoporos Int; 2001 Dec; 12(12):1020-5. PubMed ID: 11846327
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women.
Saitta A; Altavilla D; Cucinotta D; Morabito N; Frisina N; Corrado F; D'Anna R; Lasco A; Squadrito G; Gaudio A; Cancellieri F; Arcoraci V; Squadrito F
Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1512-9. PubMed ID: 11557681
[TBL] [Abstract][Full Text] [Related]
9. Biological effects of hormone replacement therapy in relation to serum estradiol levels.
Yasui T; Uemura H; Tezuka M; Yamada M; Irahara M; Miura M; Aono T
Horm Res; 2001; 56(1-2):38-44. PubMed ID: 11815726
[TBL] [Abstract][Full Text] [Related]
10. Relation of the -514C/T polymorphism in the hepatic lipase gene to serum HDL and LDL cholesterol levels in postmenopausal women under hormone replacement therapy.
Yamakawa-Kobayashi K; Somekawa Y; Fujimura M; Tomura S; Arinami T; Hamaguchi H
Atherosclerosis; 2002 May; 162(1):17-21. PubMed ID: 11947893
[TBL] [Abstract][Full Text] [Related]
11. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.
Godsland IF
Fertil Steril; 2001 May; 75(5):898-915. PubMed ID: 11334901
[TBL] [Abstract][Full Text] [Related]
12. Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate.
Lemay A; Dodin S; Cédrin I; T-Lemay L
Clin Endocrinol (Oxf); 1995 Apr; 42(4):341-51. PubMed ID: 7750187
[TBL] [Abstract][Full Text] [Related]
13. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Manguso F; Nunziata V; Mastrantonio P; Lombardi G; Zullo F
Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
[TBL] [Abstract][Full Text] [Related]
14. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
[TBL] [Abstract][Full Text] [Related]
15. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.
Davis SR; O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Thiebaud D
Menopause; 2004; 11(2):167-75. PubMed ID: 15021446
[TBL] [Abstract][Full Text] [Related]
16. Serum lipids and apolipoproteins in Greek postmenopausal women: association with estrogen, estrogen-progestin, tibolone and raloxifene therapy.
Creatsas G; Christodoulakos G; Lambrinoudaki I; Panoulis C; Chondros C; Patramanis P
J Endocrinol Invest; 2003 Jun; 26(6):545-51. PubMed ID: 12952369
[TBL] [Abstract][Full Text] [Related]
17. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
[TBL] [Abstract][Full Text] [Related]
19. Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women.
Sendag F; Karadadas N; Ozsener S; Bilgin O
Arch Gynecol Obstet; 2002 Jan; 266(1):38-43. PubMed ID: 11998963
[TBL] [Abstract][Full Text] [Related]
20. Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk.
Cerquetani E; Vitale C; Mercuro G; Fini M; Zoncu S; Rosano GM
Gynecol Endocrinol; 2004 Jun; 18(6):291-8. PubMed ID: 15497491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
